Similar articles

• [Myocardial cellular mechanism of action of calcium antagonists].

  Ferrari R, Boffa GM, Ciampalini G, Ceconi C. Ferrari R, et al. Cardiologia. 1985 Feb;30(2):77-89. Cardiologia. 1985. PMID: 3905004 Review. Italian. No abstract available.
• Calcium channel blockers: rationale for their clinical use.

  Conti CR. Conti CR. J Fla Med Assoc. 1981 Nov;68(11):883-6. J Fla Med Assoc. 1981. PMID: 6120992 No abstract available.
• Effects of verapamil and propranolol on changes in extracellular K+, pH, and local activation during graded coronary flow in the pig.

  Watanabe I, Johnson TA, Engle CL, Graebner C, Jenkins MG, Gettes LS. Watanabe I, et al. Circulation. 1989 Apr;79(4):939-47. doi: 10.1161/01.cir.79.4.939. Circulation. 1989. PMID: 2564324
• The haemodynamic effects of nifedipine, verapamil and diltiazem in patients with coronary artery disease. A review.

  Soward AL, Vanhaleweyk GL, Serruys PW. Soward AL, et al. Drugs. 1986 Jul;32(1):66-101. doi: 10.2165/00003495-198632010-00004. Drugs. 1986. PMID: 2874975 Review.
• Calcium antagonists and adenine nucleotide metabolism in rat heart.

  Nigdikar SV, Bowditch J, Dow JW. Nigdikar SV, et al. Cardiovasc Res. 1986 Aug;20(8):604-8. doi: 10.1093/cvr/20.8.604. Cardiovasc Res. 1986. PMID: 3491685